Merck partner NewLink grabs up to $76M in Ebola vax funding from feds


On the heels of crushing Phase III results for its pancreatic cancer candidate, NewLink Genetics has won a lifeline from the U.S. government. The biotech nabbed up to $76 million in BARDA funding to advance its Merck-licensed Ebola vaccine.

Through an initial tranche, the Biomedical Advanced Research and Development Authority will provide $24.8 million to prep the manufacturing process for the vaccine and to support clinical trials needed for a regulatory nod. Another $51 million in options could be awarded down the road.

The rVSV-ZEBOV vaccine, which Merck & Co. licensed from NewLink in late 2014, won FDA and EMA milestones this summer in a push toward licensure. Merck plans to submit the vaccine for approval by the end of 2017 as part of a partnership with Gavi; through that deal, the Vaccine Alliance will pay $5 million to build a stockpile.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

For Ames, IA-based NewLink, the support funds come after the biotech announced poor Phase III trial results for its pancreatic cancer vaccine algenpantucel-L, a development that gutted shares and prompted a restructuring. The biotech downsized by 100 employees and reduced manufacturing capacity and HQ space.

In the wake of the trial failure, NewLink pivoted to its Ebola vaccine, which has seen rapid advancement following the 2014 outbreak. In a Phase III ring study, the vaccine protected 100% of subjects.

That the Merck-NewLink Ebola vaccine is moving toward the finish line is likely welcome news to some disease experts, who worried that the Zika outbreak could divert attention and leave Ebola work unfinished. With the deadly Ebola outbreak waning in 2015, pharmaceutical companies with promising candidates saw their trial options narrow as it became tougher to test effectiveness.

Aside from Merck, Big Pharma player GlaxoSmithKline has pushed an Ebola vaccine candidate into Phase III. Smaller companies Novavax, Profectus Biosciences and Inovio are working in the space as well.

Related Articles:
After PhIII disaster, NewLink Genetics plots reorganization
NewLink’s pancreatic cancer vax fails PhIII, platform under scrutiny
Merck's Ebola vaccine grabs FDA, EMA milestones in push toward licensure
Complacency could derail Ebola progress, experts warn
Merck to submit Ebola vaccine for regulatory approval in 2017
Merck Ebola vaccine posts 100% efficacy in PhIII
Ebola vaccines left hanging as GSK, Merck, J&J scramble for trial volunteers

Suggested Articles

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.